CD274 and nonpapillary renal cell carcinoma: McDermott et al. reported an association between high expression of a gene set related to myeloid inflammation and reduced PFS of metastatic ccRCC patients treated with atezolizumab (anti-PD-L1), alone or combined with bevacizumab, in the IMmotion150 trial [36].